Latest Centocor Stories
Emerging Therapies, Especially IL-17 Inhibitors, Have Potential Relative to Current Therapies in Improving Psoriatic Plaques, According to Findings from Decision Resources Group BURLINGTON,
NEW BRUNSWICK, N.J., July 21, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has approved the repurchase of up to $5 billion of the
-- Deals span new approaches for cancer, diabetes, autoimmune disease and Alzheimer's, exciting technologies such as 3-D printing for trauma use, sedation monitoring, cardiac remodeling, probiotics
The Firm is representing hundreds of women who have filed vaginal mesh lawsuits against Johnson & Johnson’s Ethicon unit in state and federal courts. New
- More than 30 major product filings planned through 2016 NEW BRUNSWICK, N.J., May 22, 2014 /PRNewswire/ -- At a meeting today with members of the investment community, senior leaders from
Study Evaluating Novel Investigational IL-17 Receptor Antibody Meets All Primary and Secondary Endpoints THOUSAND OAKS, Calif.
European Dermatologists Indicate that Fewer than Half of Their Severe Patients are being Treated with a Biologic, According to Findings from Decision Resources Group BURLINGTON, Mass., May
NEW BRUNSWICK, N.J., April 29, 2014 /PRNewswire/ -- Johnson & Johnson today announced that its affiliate Janssen Pharmaceutica NV (Janssen) has entered into a novel collaboration with the
NEW BRUNSWICK, N.J., April 23, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a review of its Medical Devices & Diagnostics business for the investment
Results from Phase 2b X-PLORE Study through Week 40 Report Efficacy of Guselkumab across Multiple Dosing Regimens and Compared with Adalimumab DENVER, March 24, 2014 /PRNewswire/ -- New findings
- A trick or prank.